Literature DB >> 29079662

Endovascular treatment for cerebral vasospasm following aneurysmal subarachnoid hemorrhage: predictors of outcome and retreatment.

Jennifer D Sokolowski1, Ching-Jen Chen1, Dale Ding2, Thomas J Buell1, Daniel M Raper1, Natasha Ironside3, Davis G Taylor1, Robert M Starke4, Kenneth Liu1.   

Abstract

OBJECTIVE: Although endovascular therapy has been widely adopted for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH), its effect on clinical outcomes remains incompletely understood. The aims of this retrospective cohort study are to evaluate the outcomes of endovascular intervention for post-aSAH vasospasm and identify predictors of functional independence at discharge and repeat endovascular vasospasm treatment.
METHODS: We assessed the baseline and outcomes data for patients with aSAH who underwent endovascular vasospasm treatment at our institution, including intra-arterial (IA) vasodilator infusion and angioplasty. Statistical analyses were performed to determine factors associated with good outcome at discharge (modified Rankin Scale 0-2) and repeat endovascular vasospasm treatment.
RESULTS: The study cohort comprised 159 patients with a mean age of 52 years. Good outcome was achieved in 17% of patients at discharge (26/150 patients), with an in-hospital mortality rate of 22% (33/150 patients). In the multivariate analysis, age (OR 0.895; p=0.009) and positive smoking status (OR 0.206; p=0.040) were negative independent predictors of good outcome. Endovascular retreatment was performed in 34% (53/156 patients). In the multivariate analysis, older age (OR 0.950; p=0.004), symptomatic vasospasm (OR 0.441; p=0.046), initial treatment with angioplasty alone (OR 0.096; p=0.039), and initial treatment with combined IA vasodilator infusion and angioplasty (OR 0.342; p=0.026) were negative independent predictors of retreatment.
CONCLUSION: We found a modest rate of functional independence at discharge in patients with aSAH who underwent endovascular vasospasm treatment. Older patients and smokers had worse functional outcomes at discharge. Initial use of angioplasty appears to decrease the need for subsequent retreatment. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  aneurysm; angioplasty; balloon; stroke; subarachnoid

Mesh:

Substances:

Year:  2017        PMID: 29079662     DOI: 10.1136/neurintsurg-2017-013363

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  Computed tomography perfusion imaging after aneurysmal subarachnoid hemorrhage can detect cerebral vasospasm and predict delayed cerebral ischemia after endovascular treatment.

Authors:  Koji Omoto; Ichiro Nakagawa; Fumihiko Nishimura; Shuichi Yamada; Yasushi Motoyama; Hiroyuki Nakase
Journal:  Surg Neurol Int       Date:  2020-08-08

2.  Stent-Retriever Angioplasty for Recurrent Post-Subarachnoid Hemorrhagic Vasospasm - A Single Center Experience with Long-Term Follow-Up.

Authors:  Hyon-Jo Kwon; Jeong-Wook Lim; Hyeon-Song Koh; BumSoo Park; Seung-Won Choi; Seon-Hwan Kim; Jin-Young Youm; Shi-Hun Song
Journal:  Clin Neuroradiol       Date:  2018-08-06       Impact factor: 3.649

3.  Non-compliant and compliant balloons for endovascular rescue therapy of cerebral vasospasm after spontaneous subarachnoid haemorrhage: experiences of a single-centre institution with radiological follow-up of the treated vessel segments.

Authors:  Alexander Neumann; Jan Küchler; Claudia Ditz; Kara Krajewski; Jan Leppert; Peter Schramm; Hannes Schacht
Journal:  Stroke Vasc Neurol       Date:  2020-07-23

4.  Percutaneous Trigeminal Nerve Stimulation Induces Cerebral Vasodilation in a Dose-Dependent Manner.

Authors:  Chunyan Li; Timothy G White; Kevin A Shah; Wayne Chaung; Keren Powell; Ping Wang; Henry H Woo; Raj K Narayan
Journal:  Neurosurgery       Date:  2021-05-13       Impact factor: 4.654

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.